Equibles does not estimate personal net worth.
Collegium Pharmaceutical, Inc reported in an 8-K filed May 12, 2026 that Scott Dreyer was terminated as Executive Vice President and Chief Commercial Officer, effective August 30, 2026. The proxy statement of Collegium Pharmaceutical, Inc reports total compensation of $3,041,212 for Scott Dreyer in fiscal 2025, including a base salary of $523,236. Disclosed compensation is on record for 6 fiscal years. Scott Dreyer has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Collegium Pharmaceutical, Inc on May 7, 2026. The companies whose calls Scott Dreyer spoke on are classified in the Healthcare sector.
“On May 11, 2026, the Company announced that Scott Dreyer, Executive Vice President and Chief Commercial Officer of the Company will depart from his positions at the Company effective August 30, 2026. Mr. Dreyer's departure will be treated as a termination without cause pursuant to the terms of his existing employment agreement with the Company.”
“Our lead growth driver, Jornay PM, is off to a strong start to the year, building on the positive momentum we generated in 2025. In the first quarter of 2026, we grouped prescriptions, prescribers, and market share year over year.”
“ADHD is a large and growing market, which Collegium first entered in 2024 following our acquisition of Joint APM. There are roughly 22 million patients in the U.S. across pediatrics, adolescents, and adults, with about 111 million prescriptions written in 2025.”
“I want to start by recognizing the hard work of our people, which enabled us to be operational on day one after closing the BDSI transaction. Collegium is firmly established as the leader in responsible pain management.”
Proxy statement
Start not stated–2026-08-30
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Commercial Officer | $523,236 | $3,041,212 |
| 2024 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Commercial Officer | $489,507 | $2,791,375 |
| 2023 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Commercial Officer | $462,281 | $2,612,380 |
| 2022 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Commercial Officer | $440,265 | $2,217,192 |
| 2021 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Commercial Officer | $418,635 | $2,381,596 |
| 2020 | Collegium Pharmaceutical, Inc (COLL) | Executive Vice President and Chief Commercial Officer | $395,015 | $1,716,467 |
